Search
for

    Learn

    5 / 8 results

      learn HMI-115

      much-hyped research compound targeting prolactin receptor in scalp

      learn GHK-Cu

      a copper peptide showing promise in both regrowth and reversing gray hair

      learn Caffeine

      the stimulant you know and love can be used topically to stimulate hair

      learn Minoxidil

      An essential vasodilator with some anti-androgenic effects, has excellent safety record

      learn Tretinoin

      the gold standard retinoid in dermatology that's also helpful for hair regrowth alongside Minoxidil

    Research

    5 / 1000+ results

    Community Join

    5 / 171 results
      Diffuse hair loss and scalp biopsies

      community Diffuse hair loss and scalp biopsies

      in Research  692 upvotes 4 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  42 upvotes 4 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community The MPB itch aka DHT itch is very real.

      in Chat  9 upvotes 1 year ago
      Hair loss itch is caused by DHT attacking follicles and stimulating nerves. Finasteride users who respond well don't experience this itch.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.